cyrilzakka/clinical-trials huggingface dataset:
Cardiopulmonary Outpatient Rehabilitation Using Mobile Technology

This is a randomized controlled trial of the feasibility and utility of implementing a smartphone application (MVN) to maintain compliance with a Heart Healthy lifestyle after discharge from a cardiac outpatient rehabilitation program. Patients will be randomized into one of two groups: usual care (control: UC) or Movn mobile application (intervention: MVN). This study will improve and strengthen data collection from this at-risk patient population by recording baseline clinical and psycho social measures while gaining insight into self-reporting of physical activity and frequency between the UC and MVN groups.


Eligibility Criteria:
Inclusion Criteria:

* Current participants in The Joan and Joel Smilow Cardiac Rehabilitation and Prevention Center (JJCRPC) of Rusk Rehabilitation Patient within two weeks of completing outpatient cardiac rehabilitation
* Clinically stable: moderate to low risk strata by standardized clinical assessment
* Clinically stable: moderate to low risk strata by standardized clinical assessment
* no infections
* no unstable arrhythmias, aortic stenosis, thrombophlebitis, dissecting aneurysm or symptomatic anemia
* controlled blood pressure-resting diastolic \<100 mmHg, systolic \<180mmHg
* no uncompensated heart failure NYHA Class 3-4
* stable angina (no chest pain for month)
* no 2nd or 3rd degree heart block
* no uncontrolled high grade exercise induced ventricular ectopy-hemodynamically stable
* Own an iPhone (version 3 or above), an iPad, or an iPod touch (version 4 or higher) or Android phone or tablet
* Ability to use and comfortable with using mobile health technology to monitor physical and psychosocial health
* Is comfortable using mobile applications
* English language fluency
* Ability to provide informed consent

Exclusion Criteria:

* Patients who do not fulfill all inclusion criteria stated above.
Salivary Flow Rate Response to Electrostimulation in HD Patients

Xerostomia is a subjective complaint of dry mouth, whereas hyposalivation is an objective decreased of salivary flow. Hyposalivation was reported in 28.8 % of haemodialysis (HD) patients (Bruzda-Zwiech, 2014).

Stimulation of the salivary glands can be induced mechanically (for example, by chewing gum or acupressure) or through medications (such as pilocarpine, cevimeline, angiotensin-converting-enzyme inhibitors and angiotensin-receptor blockers) or by electrostimulation as transcutnaeous electrical nerve stimulation (TENS) (Bossola and Tazza, 2012).

Eighty HD patients (40 diabetics and 40 nondiabetics) will receive 20 minutes of TENS on skin over bilateral parotid gland, 3 times weekly for 3 weeks to investigate the hyposalivation response of diabetic and non diabetic HD patients to TENS.

Eligibility Criteria:
Inclusion Criteria:

* Eighty HD patients (40 diabetics and 40 non diabetics)
* HD at least from three month
* saliva flow less than or equal 0.15 millilitre per minute

Exclusion Criteria:

* pulmonary or cardiac disorders
* drugs to treat hyposalivation
* salivary glands inflammation, tumor, and autoimmune diseases.
* smokers and alcholics
The Value of PET Imaging Targeting Granzyme B in Predicting Efficacy and Prognosis in T-NK Cell Lymphoma

The study on the value of PET imaging targeting granzyme B in predicting the efficacy and prognosis of T-NK cell lymphoma.

The investigators will number all participants, create a medical record file, and record their basic information (gender, age) as well as contact information and medical history information. All participants will undergo 68Ga-grazytracer PET at baseline and after one course of immunotherapy.

Eligibility Criteria:
Inclusion Criteria:

1. Age \> 18 years, regardless of gender.
2. Histopathologically confirmed diagnosis of T-NK cell lymphoma.
3. Newly diagnosed and untreated patients or refractory/relapsed patients preparing to undergo immunotherapy.
4. Availability of complete clinicopathological and follow-up data.
5. Signed and dated informed consent form.

Exclusion Criteria:

1. Patients who have previously received anti-tumor therapy.
2. Patients with a history of other malignancies.
3. Incomplete clinical information or imaging data.
4. Concurrent other malignant tumors.
5. Patients with severe medical conditions deemed unsuitable for participation in this clinical study by the investigator, such as severe cardiopulmonary insufficiency or severe hepatic and renal dysfunction.
6. Poor compliance.
Allogenic Plasma Aliquots in the Treatment of Ligneous Conjunctivitis

Allogenic plasma aliquots, used as eye drops, will provide a source of plasminogen in the treatment of ligneous conjunctivitis. The investigational product will be available through written request from the Sponsor-Investigator to Canadian Blood Services, as approved by Health Canada.

Ligneous conjunctivitis is a chronic progressive disorder of the conjunctival mucosa which occurs secondary to plasminogen deficiency. The condition is characterized by thick, fibrous pseudo membranes adherent to the conjunctival surface of the eye lid.The investigational product, allogenic plasma aliquots, is a source of plasminogen. It will be used as eye drops, to treat recurrences of these pseudo membranes by providing the plasminogen required for fibrinolysis. The allogenic plasma aliquots are prepared by Canadian Blood Services. An initial supply of 680 vials was made available through the Special Access program, upon approval by Health Canada. Through this Clinical Trial, additional allogenic plasma aliquots will be available when required to treat recurrences of the pseudo membranes. The study has been conditionally approved by local HREB, pending registration with clinicaltrials.gov

Eligibility Criteria:
Inclusion Criteria:

* Subject diagnosed with ligneous conjunctivitis associated with Type 1 plasminogen deficiency

Exclusion Criteria:

* Subject has concurrent eye disease which prevents use of the investigational drug
Vascular Function in Adolescent, Diabetic Children

The objectives of this investigator initiated study are to:

1. Determine if and when vascular abnormalities occur during early adolescence
2. Determine if poor diabetic control is related to vascular abnormalities.

The development of vascular plaques and vascular contractility will be assessed through the use of the SyphmgnoCor equipment.

Up to 85 Type 1 diabetic and healthy controls, 12-14 years of age, will be recruited for the study. Once the Permission/Assent form has been completed, a cuff will be applied to the arm and the pressure tonometer will be used on various vessels. Cardiovascular data will be recorded. The procedure is non-invasive, will last approximately 10 minutes and will be performed during a routine clinic visit. Onset of diabetes and level of diabetic control as measured by the most recent Hbg A1c (relative to the study visit) will be obtained from the medical record. Microalbumin levels covering the prior 12 months will be collected from the medical record of diabetic subjects.

Eligibility Criteria:
Inclusion Criteria:

* Boys and girls ages 12-14 years who have Type 1 diabetes or are healthy controls

Exclusion Criteria:

* Children and adolescents who do not meet inclusion criteria
Magnetic Field Application in Patellofemoral Pain Syndrome

The purpose of this study is to examine the effect of magnetic field application used in the treatment of patellofemoral pain.

The aim of this randomized controlled study is to examine the effect of magnetic field application used in the treatment of patellofemoral pain.

The main question it aims to answer is;

Is magnetic field therapy applied in addition to conventional treatment effective in reducing pain in individuals with Patellofemoral pain syndrome?

Eligibility Criteria:
Inclusion Criteria:

* Having been diagnosed with patellofemoral pain syndrome by an orthopedic physician
* Volunteering to participate in the study
* Having pain for more than eight weeks
* Patients who did not undergo surgery

Exclusion Criteria:

* Patients diagnosed with rheumatological disease
* Patients who have previously had steroid injections in the knee area
* Patients with entrapment neuropathy and deformity in the lower extremity
* Patients who are pregnant
* Patients suffering from scoliosis,
* Patients who use non-steroidal anti-inflammatory and antidepressant regularly for any reason
Impact of Music Therapy on Intraoperative Patient Comfort During Cataract Surgery With Topic Anesthesia

Cataract surgery with topic anesthesia is anxiety provoking. This operative stress can increase pain perception and blood pressure. This discomfort can lead to non-compliance with immobility and potentially lead to intraoperative and postoperative complications.

Pharmacological means are limited to reduce anxiety. Only anxiolytics could be effective but at the cost of side effects not compatible with surgery.

Music Care is a "digital treatment" allowing the diffusion of music with a U-shaped sequence using the principles of hypnoanalgesia.

The objective of this study is to evaluate the effectiveness of the MusicCare listening device on the anxiety of patients during cataract surgery with topic anesthesia


Eligibility Criteria:
Inclusion Criteria:

* Cataract surgery with topical anesthesia

Exclusion Criteria:

* Hearing impaired patient
A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer

This is a Phase 1b/2 study to investigate the efficacy and safety of LBL-007 plus tislelizumab when administered in combination with bevacizumab plus fluoropyrimidine, and LBL-007 in combination with bevacizumab plus fluoropyrimidine versus bevacizumab plus fluoropyrimidine to participants with colorectal cancer.


Eligibility Criteria:
Inclusion Criteria:

* Participant must have measurable disease as defined per RECIST version 1.1
* Has a histologically confirmed colorectal adenocarcinoma with metastatic or unresectable disease (Stage IV as defined by American Joint Committee on Cancer \[AJCC\] 8th edition)
* No prior systemic therapy for colorectal cancer (CRC) in the metastatic setting except for the induction treatment of first-line therapy. Note: Local regional treatment performed during induction systemic treatment is allowed
* Participants who have completed the first-line induction treatment, with an overall response of stable disease or better. The duration of induction treatment should be completed within approximately 6 months. The first dose of study treatment needs to occur within 2 weeks (for 2-week regimen) or 3 weeks (for 3-week regimen) to 6 weeks after Day 1 of the last cycle of induction therapy

Exclusion Criteria:

* Participants whose disease has become resectable at the investigator's discretion during or after induction treatment are not eligible
* Progressive disease occurred less than 6 months from completion of any prior neoadjuvant therapy (ie, chemotherapy with or without radiotherapy) or adjuvant therapy (ie, chemotherapy with or without radiotherapy), whichever occurred later
* Participants who have been treated with anti-epidermal growth factor receptor (EGFR) antibody in the induction treatment
* Any prior therapy targeting T-cell stimulation or checkpoint pathways
* Participants with B-raf proto-oncogene, serine/threonine kinase (BRAF)V600E mutations
* Have locally or centrally confirmed microsatellite instability-high (MSI-H) by polymerase chain reaction (PCR) method or dMMR by immunohistochemistry (IHC) method

Note: Other protocol defined criteria may apply.
Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia

This study will evaluate the efficacy of uproleselan (GMI-1271), a specific E-selectin antagonist, in combination with chemotherapy to treat relapsed/refractory AML, compared to chemotherapy alone. The safety of uproleselan when given with chemotherapy will also be investigated in patients with relapsed/refractory AML


Eligibility Criteria:
Inclusion Criteria:

* ≥18 years and ≤75 years in age
* Patients with relapsed or refractory AML
* No more than one prior stem cell transplant
* Has not received the chemotherapy regimen to be used for induction on this trial
* Is considered medically eligible to receive the chemotherapy regimen to be used for induction on this trial

Exclusion Criteria:

* Patients with acute promyelocytic leukemia, acute leukemia of ambiguous lineage (biphenotypic leukemia), chronic myeloid leukemia with myeloid blast crisis, or secondary refractory AML.
* Active signs or symptoms of CNS involvement by malignancy.
* Stem cell transplantation ≤4 months prior to dosing.
* Any immunotherapy or radiotherapy therapy within 28 days of dosing; any other experimental therapy or chemotherapy within 14 days of dosing.
* Prior use of G-CSF, CM-CSF or plerixafor within 7 days of dosing.
* Inadequate organ function.
* Abnormal liver function.
* Known active infection with hepatitis A, B, or C, or human immunodeficiency virus.
* Moderate kidney dysfunction (glomerular filtration rate \<45 mL/min).
* Uncontrolled acute life-threatening bacterial, viral, or fungal infection.
* Clinically significant cardiovascular disease.
* Major surgery within 4 weeks of dosing.
Investigative Headgear With CPAP Mask

This investigation is designed to evaluate the at-home usability, performance, user acceptance and reliability of the Headgear with a CPAP Mask for a duration of 2-4 weeks.

Up to 300 participants will be recruited for the trial, consisting of male and female participants diagnosed with OSA and receiving CPAP or Bi-level PAP for the treatment of their OSA. These include current CPAP mask users.

Eligibility Criteria:
Inclusion Criteria:

* AHI≥5 from the diagnostic night
* ≥18 years of age
* Prescribed CPAP or Bilevel therapy for OSA
* Existing CPAP mask users

Exclusion Criteria:

* Inability to give informed consent
* Patient intolerant to PAP
* Anatomical or physiological conditions making PAP therapy inappropriate
* History of respiratory disease or CO2 retention.
* Pregnant or think they may be pregnant
* Investigated by Land Transport Safety Authority
"To Study the Impact of Balloon-occluded Retrograde Transvenous Obliteration (BRTO)/Plug Assisted Retrograde Transvenous Obliteration (PARTO) Mediated Portal Flow Modulation in Reduction of Ammonia and Improvement in Organ Volume and Functionality in Patients of Cirrhosis With LR Shunt

The informed consent will be obtained from the participants in the study. The study will be conducted on indoor patients, Department of Hepatology ILBS, New Delhi. This will be a Pilot study (sample size 25 cases in each arm) with 50% chances of each patient to randomized into each arm(1:1 randomization) .

Study Population - Patients with hepatic encephalopathy with LR shunt admitted in wards/HDU (High Dependency Unit)/LC ICU(Liver Coma ICU).

Study design-Randomized controlled Trial

Study period- 1 year.

Sample Size-Single Centre prospective RCT

* Sample size- Pilot study (sample size 25 cases in each arm)
* Follow up duration-6 months


Eligibility Criteria:
Inclusion Criteria:

* Child A and B cirrhotic patients with Gastro/lieno-renal shunt of \>8 mm.
* Covert or Overt HE
* Age 18 to 70 years

Exclusion Criteria:

* Intractable ascites
* PVT (with 100 % block )or PV Cavernoma and splenic vein thrombosis
* High risk esophageal varices (till eradicated)
* HVPG \>16 mm Hg
* HCC
* Pregnancy and lactation
* Refusal to participate in the study
Speech Pattern Evaluation and Analysis for Knowledge of AD

The goal of this observational study is to validate changes in speech as a measure of cognition in individuals at increased risk of Alzheimer's disease and related dementias (ADRD). This study aims to clarify how speech may be affected by Alzheimer's disease.

Participants will complete speech collection sessions and a survey at home using an iPad. Participants can expect to be in the study for 3 years.

Digital technology, including recorded speech, has the capability of providing a wealth of information about early changes to cognition and communication associated with developing Alzheimer's disease pathology, with the potential for highly accessible, yet low-burden measurement. In this project, researchers will recruit a subset of participants from two longitudinal, observational cohort studies enriched for individuals at risk for or living with Alzheimer's disease to record their speech at home with a mobile device, longitudinally. Our interdisciplinary team will then validate digital markers across all stages of Alzheimer's Disease and Related Dementias (ADRD), including the prodromal phase, and can enhance sensitivity and specificity of speech metrics while contributing valuable information about remote, noninvasive, and accessible assessment and disease monitoring.

Eligibility Criteria:
Inclusion Criteria:

* Must be enrolled in the Wisconsin Alzheimer's Disease Research Center (W-ADRC) Clinical Core or IMPACT studies, or in the Wisconsin Registry for Alzheimer's Prevention (WRAP)
* Cognitively unimpaired or have a diagnosis of Mild Cognitive Impairment (MCI)
* Ages 40-80 years
* Completion of a W-ADRC or WRAP study visit within the past or upcoming 12 months
* Have provided W-ADRC or WRAP with blood plasma Alzheimer's Disease

Exclusion Criteria:

* Not actively enrolled in W-ADRC or WRAP
* Diagnosis of dementia
* Impaired capacity or unwilling to consent
* Major neurological conditions
* Speech disorders
Bariatric Surgery and Male Reproductive Function

Obesity is a global public health problem. According to literature reports, as of 2016, China's obese population has reached more than 90 million and type 2 diabetes mellitus has reached more than 100 million, which has brought a serious health and economic burden to China. In addition to various health problems such as cardiovascular, osteoarthritis, and tumors, obesity can also cause abnormalities in reproductive endocrine. In women, it can cause abnormal menstruation, polycystic ovary syndrome, and male obesity can cause secondary gonadal. Hypofunction (MOSH). MOSH is an endocrine dysfunction. It is reported to have a prevalence of approximately 45% in moderate to severe obesity. In addition, studies have pointed out that the prevalence of hypogonadism in men with type 2 diabetes and obesity higher. However, there are no studies on the reproductive function of Chinese male patients after bariatric surgery. Pre- and post-operative semen will be collected for analysis to observe the effect of bariatric surgery on male reproductive function.


Eligibility Criteria:
Inclusion Criteria:

* Meet the surgical indications according to the Chinese Guidelines for Surgical Treatment of Obesity and Type 2 Diabetes (2019 Edition).
* 20 years old\< patient\<60 years old.
* Male

Exclusion Criteria:

* Incapacity of giving an informed consent.
* Drug and / or alcohol abuse.
* Scrotal injury and previous scrotal surgery.
* Use of phosphodiesterase-5 inhibitors.
* Mental illnesses that may affect compliance with clinical research, including dementia, active psychosis, major depression, or attempted suicide.
Registry of Management Strategies for Patients With COVID-19 in Healthcare Establishments

The purpose of the study is to describe medical care strategies implemented by healthcare establishments for patients affected by COVID-19

Coronavirus infection (SARS-Cov2), very contagious, is benign in the most cases but can be complicated by an acute respiratory distress syndrome, for which an invasive mechanical ventilation in resuscitation is necessary with an important mortality rate. This infection is about an important health crisis with a fast saturation of the health system.

In front of the novelty of this virus, any effective treatment has been demonstrated in humans and researches have accelerated as this pandemic continues.

First available results, in chinese population, have not demonstrated superiority of the Lopinavir/Ritonavir association versus standard care (Cao et al. 2020). In a randomized study in 62 chinese patients, Chen et al. seems to find a clinical efficacy of the Hydroxychloroquine compared to placebo. Gautret et al. has also found a decreased viral load in nasopharyngeal swabs in patients affected by COVID-19, treated by Hydroxychloroquine and by the association of Hydroxychloroquine-Azythromycine. However, these preliminary results doesn't allow to conclue on the efficacy against COVID-19.

Currently, any treatment in particular is recommanded for patients affected by COVID-19. Randomized studies on a larger scale and greater rigor at national and european level are in process to determine the efficacy of several treatments.

Pending results of these studies, healthcare establishments had to adapt and strategize to take care their patients. These strategies have rapidely evolved during this pandemy, in terms of the therapeutic clinical studies opening, the acquisition of new knowledges on COVID-19, and treatments.

Screening : All patients with a COVID-19 diagnosis who have been treated in 2020 in participant establishements will be included in the HOPICOV study.

Enrolment : On discharge from hospital, an information notice will be delivered to the patient (or at his close relative / his legal guardian) to allow him to exert his right to oppose his collection data identified as part of the treatment. Otherwise, this information might be send by letter after his discharge.

All participating centers will be encouraged to enter data as things progress to allow interim analysis and scientific communication.

Eligibility Criteria:
Inclusion Criteria:

* Any adult patient admitted to the establishment for treatment for a SARS-Cov2 infection
* Positive RT-PCR or a scanner suggestive of COVID-19 during the stay, or with a positive serology (even if carried out after the patient's discharge)
* Hospitalization \> 24h
* Patients receiving any type of care, whether it is recommended standard care or off-label treatment as part of a therapeutic clinical trial or outside the scope of clinical research

Exclusion Criteria:

* Opposition to the use of data following written patient information
* Patient transferred from another hospital to continue COVID care and whose initial care data is not available
Autopsy Follow-up of Subjects Previously Imaged With Florbetapir F 18 (18F-AV-45) PET in Trial 18F-AV-45-A07

This study is designed to test the relationship between measurements of brain amyloid using florbetapir F 18 PET imaging and true levels of amyloid plaque density as measured by histopathological assessment. The study will address the following specific aims:

1. To expand the number of subjects included in the A07 (NCT00857415) trial correlation analysis (measuring the correlation between the global visual rating of brain amyloid plaque density on an independent blinded read of the florbetapir F 18 PET scan and the cortical amyloid plaque density at autopsy as assessed by histopathology for subjects in the autopsy cohort).
2. To determine the sensitivity and specificity of an independent blinded visual read assessment of the florbetapir F 18 PET scan (Aβ+ or Aβ-) versus the final blinded neuropathological assessment made at autopsy.


Eligibility Criteria:
Inclusion Criteria:

Subjects are enrolled in this study if they:

* Met entrance criteria and were enrolled and imaged in trial 18F-AV-45-A07 (NCT00857415)
* Gave informed consent for the 18F-AV-45-A07 (NCT00857415) study procedures and brain donation consistent with the legal requirements of the State in which they are enrolled and the State in which they die
* Consent to participate in the 18F-AV-45-A16 (NCT01447719) extension protocol, if required by the IRB
* Reconfirm their consent to a research brain autopsy, if required by the IRB.